

ESCALATED REGIMEN OF HEPATITIS B VACCINE IN CHILDHOOD HEMATOLOGICAL MALIGNANCIES WHILE ON CHEMOTHERAPY

Nobokrishna Ghosh¹, MA Mannan², Forhad Monjur³, Farhana Rizwan⁴
and AFM Salim¹

¹Department of Pediatrics, ³Department of Pathology, Institute of Child Health (ICH) and Shishu Sasthya Foundation Hospital, Mirpur, Dhaka; ²Department of Pediatrics, Bangobandhu Sheikh Mujeeb Medical University (BSMMU), Dhaka; ⁴Department of Pharmacy, East West University, Dhaka, Bangladesh

Abstract. This prospective study was conducted to find the effective vaccination schedule against hepatitis B virus (HBV) infection for children with hematological malignancies. Sixty patients ages 2-15 years old with hematological malignancies on chemotherapy, negative for hepatitis B surface antigen (HBsAg) and never vaccinated for HBV before, were vaccinated with 40 µg of vaccine at 0, 1 and 2 months. Antibody titers were measured 6 weeks after administration of last dose. Out of the 60 children enrolled, 5 died during the course of treatment and 4 dropped out before completion, leaving 51 for final analysis. More than 70% exhibited protective levels of antibodies (>10 mIU/ml) against hepatitis B virus. There were no significant effects of age or sex on the antibody response, although antibodies were higher among girls (90.9%) than boys (65%). Patients with non-Hodgkin's lymphoma were found to exhibit a better antibody response than leukemic children ($p = 0.024$). Children with hematological cancers should be vaccinated with an escalated regimen of the vaccine.

Key word: hepatitis B virus, vaccination schedule, HBsAg, children, hematological malignancies

Correspondence: Professor AFM Salim, Department of Pediatrics, Institute of Child Health (ICH) and Shishu Sasthya Foundation Hospital, 6/2 Barabagh, Mirpur-2, Dhaka -1206, Bangladesh.

Tel: +880 2 8023894, 8023895 ext 511; Fax: +880 2 8014896

E-mail: the.salims@gmail.com